Sunshine Biopharma (SBFM)

$1.73 -0.07 (-3.89%)
Market Cap 901,000.00
Revenue (ttm) 36.31M
Net Income (ttm) -5.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -16.47%
Debt to Equity Ratio 0.00
Volume 108,000
Avg Vol 2,021,302
Day's Range N/A - N/A
Shares Out 501,000.00
Stochastic %K 0%
Beta 1.13
Analysts Sell
Price Target $56.00

Company Profile

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 954 330 0684
Address:
333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, United States
contra7
contra7 Jul. 20 at 11:43 PM
$SBFM
0 · Reply
MB66
MB66 Jul. 20 at 10:56 PM
$SBFM
1 · Reply
hotslots
hotslots Jul. 20 at 9:24 PM
$SBFM maybe the buyout is lower than my original guess. Maybe 3 million
1 · Reply
Masterrunner
Masterrunner Jul. 20 at 8:46 PM
$SBFM Atl (all time lows) after Atl. You can’t average down when there is no floor. Stay away! NFA.
0 · Reply
MomentumSqueeze
MomentumSqueeze Jul. 20 at 8:29 PM
$SBFM 👀
0 · Reply
Masterrunner
Masterrunner Jul. 20 at 3:42 PM
$SBFM They rehashed this "PR" from 2022?
2 · Reply
contra7
contra7 Jul. 20 at 3:33 PM
$SBFM More VALUE SURFACING ahead of disclosure. This development increases IP valuation exponentially.
0 · Reply
MB66
MB66 Jul. 20 at 2:15 PM
$SBFM https://sunshinebiopharma.com/wp-content/uploads/2026/07/20260720_SBFM_Press-Release_New-JMC-Publication.pdf
0 · Reply
FatCatFenix
FatCatFenix Jul. 20 at 1:58 PM
$SBFM Well we know where this is heading looking at the tape, algorithm keeps hunting for lower price discovery and has been hitting it for the last 4 trading days, pre market hit 1.70$ - That’s 17c pre split. It occurred to me that institutions with warrants at 2.50$ could essentially be using that as a hedge to short. The upside is protected at 2.50$ so they can have a blast shorting while volume is low.
0 · Reply
hotslots
hotslots Jul. 17 at 10:43 PM
$SBFM after hours announcement??
0 · Reply
Latest News on SBFM
Sunshine Biopharma announces publication of new results on MR1-114

2026-07-20T12:45:19.000Z - 12 hours ago

Sunshine Biopharma announces publication of new results on MR1-114

Sunshine Biopharma and University of Arizona Publish Significant New Research Findings

Jul 20, 2026, 8:30 AM EDT - 12 hours ago

Sunshine Biopharma and University of Arizona Publish Significant New Research Findings

Sunshine Biopharma receives Canadian approval for generic Arimidex

2026-06-25T12:20:47.000Z - 25 days ago

Sunshine Biopharma receives Canadian approval for generic Arimidex

Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)

Jun 25, 2026, 8:00 AM EDT - 25 days ago

Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)

Sunshine Biopharma announces Canadian approval for Rivaroxaban

2026-06-01T12:23:56.000Z - 7 weeks ago

Sunshine Biopharma announces Canadian approval for Rivaroxaban

Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)

Jun 1, 2026, 8:00 AM EDT - 7 weeks ago

Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)

R

Sunshine Biopharma Inc trading halted, news pending

2026-05-29T23:55:22.000Z - 7 weeks ago

Sunshine Biopharma Inc trading halted, news pending

Sunshine Biopharma issued U.S. patent for coronavirus treatment tech

2026-05-29T13:11:09.000Z - 7 weeks ago

Sunshine Biopharma issued U.S. patent for coronavirus treatment tech

Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology

May 29, 2026, 8:00 AM EDT - 7 weeks ago

Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology

Sunshine Biopharma announces 1-for-10 reverse split of its common stock

2026-05-28T14:49:55.000Z - 7 weeks ago

Sunshine Biopharma announces 1-for-10 reverse split of its common stock

Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing

May 28, 2026, 9:00 AM EDT - 7 weeks ago

Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing

Sunshine announces approval of generic amoxicillin formulation for Canada

2026-05-21T11:17:11.000Z - 2 months ago

Sunshine announces approval of generic amoxicillin formulation for Canada

Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin

May 21, 2026, 7:00 AM EDT - 2 months ago

Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin

3 Penny Stocks to Watch Now, 5/19/26

2026-05-19T16:21:43.000Z - 2 months ago

3 Penny Stocks to Watch Now, 5/19/26

AIIO GOVX

Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering

May 19, 2026, 12:05 PM EDT - 2 months ago

Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering

Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering

May 18, 2026, 12:15 PM EDT - 2 months ago

Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering

Why Is Penny Stock Sunshine Biopharma (SBFM) Up Today?

2026-05-18T12:55:34.000Z - 2 months ago

Why Is Penny Stock Sunshine Biopharma (SBFM) Up Today?

Sunshine Biopharma files to sell 5.825M common units

2026-05-12T21:20:04.000Z - 2 months ago

Sunshine Biopharma files to sell 5.825M common units

Sunshine Biopharma reports FY25 EPS ($1.44) vs. ($7.32) last year

2026-04-06T12:53:12.000Z - 3 months ago

Sunshine Biopharma reports FY25 EPS ($1.44) vs. ($7.32) last year

Sunshine Biopharma expects to reduce expenses by $2M-$3M in 2026

2026-04-06T12:52:43.000Z - 3 months ago

Sunshine Biopharma expects to reduce expenses by $2M-$3M in 2026

Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

Apr 6, 2026, 8:30 AM EDT - 3 months ago

Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Oct 28, 2025, 2:10 PM EDT - 9 months ago

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Sunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidone

2025-10-28T11:50:45.000Z - 9 months ago

Sunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidone

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Oct 28, 2025, 7:45 AM EDT - 9 months ago

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Sunshine Biopharma announces commercial launch of doxycycline in Canada

2025-10-20T11:50:37.000Z - 9 months ago

Sunshine Biopharma announces commercial launch of doxycycline in Canada

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Oct 20, 2025, 7:45 AM EDT - 9 months ago

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Sunshine Biopharma’s Nora Pharma launches pravastatin

2025-10-16T11:50:20.000Z - 9 months ago

Sunshine Biopharma’s Nora Pharma launches pravastatin

Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin

Oct 16, 2025, 7:45 AM EDT - 9 months ago

Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

Oct 14, 2025, 10:45 AM EDT - 9 months ago

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)

Oct 14, 2025, 8:50 AM EDT - 9 months ago

Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)

Sunshine Biopharma allocates $5M for investment in bitcoin

2025-10-14T11:20:53.000Z - 9 months ago

Sunshine Biopharma allocates $5M for investment in bitcoin

Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience

Oct 14, 2025, 7:00 AM EDT - 9 months ago

Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience

Sunshine Biopharma, University of Arizona develop series of protease inhibitors

2025-10-09T12:26:07.000Z - 10 months ago

Sunshine Biopharma, University of Arizona develop series of protease inhibitors

Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections

Oct 9, 2025, 8:00 AM EDT - 10 months ago

Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections

Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

Jul 2, 2025, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

Jun 11, 2025, 8:30 AM EDT - 1 year ago

Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

May 15, 2025, 4:15 PM EDT - 1 year ago

Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

May 6, 2025, 8:30 AM EDT - 1 year ago

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Apr 21, 2025, 8:30 AM EDT - 1 year ago

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Apr 3, 2025, 10:50 AM EDT - 1 year ago

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Apr 2, 2025, 1:20 PM EDT - 1 year ago

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Apr 1, 2025, 5:09 PM EDT - 1 year ago

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Mar 10, 2025, 9:00 AM EDT - 1 year ago

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Jan 21, 2025, 8:00 AM EST - 1 year ago

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Jan 15, 2025, 8:00 AM EST - 1 year ago

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Dec 9, 2024, 7:30 AM EST - 1 year ago

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Sunshine Biopharma Launches a New Generic Prescription Drug

Dec 4, 2024, 4:05 PM EST - 1 year ago

Sunshine Biopharma Launches a New Generic Prescription Drug

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Dec 2, 2024, 8:00 AM EST - 1 year ago

Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Nov 6, 2024, 8:00 AM EST - 1 year ago

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Sunshine Biopharma Launches Two New Generic Prescription Drugs

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sep 4, 2024, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Aug 26, 2024, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Aug 19, 2024, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

Sunshine Biopharma Announces Reverse Stock Split

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Announces Reverse Stock Split

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Feb 15, 2024, 9:15 AM EST - 2 years ago

Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Feb 13, 2024, 9:00 AM EST - 2 years ago

Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering

Sunshine Biopharma Moves Principal Office to New York City

Dec 4, 2023, 8:30 AM EST - 2 years ago

Sunshine Biopharma Moves Principal Office to New York City

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Nov 13, 2023, 8:30 AM EST - 2 years ago

Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Sep 21, 2023, 9:05 PM EDT - 3 years ago

Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

Aug 11, 2023, 8:30 AM EDT - 3 years ago

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

May 16, 2023, 2:15 PM EDT - 3 years ago

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.0 Million Private Placement Priced At-the-Market for Sunshine Biopharma, Inc. (NASDAQ:SBFM)

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

May 16, 2023, 9:58 AM EDT - 3 years ago

Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

May 12, 2023, 8:00 AM EDT - 3 years ago

Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market

contra7
contra7 Jul. 20 at 11:43 PM
$SBFM
0 · Reply
MB66
MB66 Jul. 20 at 10:56 PM
$SBFM
1 · Reply
hotslots
hotslots Jul. 20 at 9:24 PM
$SBFM maybe the buyout is lower than my original guess. Maybe 3 million
1 · Reply
Masterrunner
Masterrunner Jul. 20 at 8:46 PM
$SBFM Atl (all time lows) after Atl. You can’t average down when there is no floor. Stay away! NFA.
0 · Reply
MomentumSqueeze
MomentumSqueeze Jul. 20 at 8:29 PM
$SBFM 👀
0 · Reply
Masterrunner
Masterrunner Jul. 20 at 3:42 PM
$SBFM They rehashed this "PR" from 2022?
2 · Reply
contra7
contra7 Jul. 20 at 3:33 PM
$SBFM More VALUE SURFACING ahead of disclosure. This development increases IP valuation exponentially.
0 · Reply
MB66
MB66 Jul. 20 at 2:15 PM
$SBFM https://sunshinebiopharma.com/wp-content/uploads/2026/07/20260720_SBFM_Press-Release_New-JMC-Publication.pdf
0 · Reply
FatCatFenix
FatCatFenix Jul. 20 at 1:58 PM
$SBFM Well we know where this is heading looking at the tape, algorithm keeps hunting for lower price discovery and has been hitting it for the last 4 trading days, pre market hit 1.70$ - That’s 17c pre split. It occurred to me that institutions with warrants at 2.50$ could essentially be using that as a hedge to short. The upside is protected at 2.50$ so they can have a blast shorting while volume is low.
0 · Reply
hotslots
hotslots Jul. 17 at 10:43 PM
$SBFM after hours announcement??
0 · Reply
contra7
contra7 Jul. 17 at 4:04 PM
$SBFM The 13G filed last Wednesday was a direct result of the Aegis warrant solicitation for the settlement of series B warrants. This is the type of filing you see as last minute housekeeping before a deal is finalized. To be clear, the Chamoun settlement had nothing to do with any shady business between him and SBFM. Chamoun as the founder of NORA threatened litigation against SBFM because he knew and understood the endgame here, nothing more nothing less. He never even actually filed a lawsuit because he knew that threatening litigation as the founder was enough for him to be taken care of at the table. An acquiring company will always derisk by settling any and all litigation threats ahead of closing a deal that’s just how these things work and Chamoun knew that. The fact that the company signed it 2 days prior than dropped after hours last Friday was the final piece of housekeeping that SBFM had to clear before the endgame which is standard in the M&A process.
1 · Reply
hotslots
hotslots Jul. 17 at 3:57 PM
$SBFM ripe for the takeover at under 4 million mc!!!
0 · Reply
Outrun_Sunshine
Outrun_Sunshine Jul. 17 at 1:27 PM
$SBFM Just want to remind the bulls who have ZERO exit strategy, and the bagholders - Market Makers make a market... when price falls, it is because there is NO market and they go searching for buyers. Price falls because there are more sellers than buyers. It isn't just because "sHorTS aRE KEEpinG thIS loW for 10 YEArs becAUSe sLILaty iS so geNIUs". The company, even if it was under a "blackout" (my totally real girlfriend lives in Canada btw, you won't be able to meet her at camp this summer) it's over now. They have no news because there is no news. Generics and godawful share structure fuckery is all they know.
1 · Reply
hotslots
hotslots Jul. 16 at 9:17 PM
$SBFM news???
0 · Reply
hotslots
hotslots Jul. 15 at 8:00 PM
$SBFM well gosh darn today was not the day
0 · Reply
contra7
contra7 Jul. 15 at 7:57 PM
$SBFM
1 · Reply
hotslots
hotslots Jul. 15 at 1:50 PM
$SBFM sale could be today. Looking for 15.50 per share
3 · Reply
Zynth
Zynth Jul. 14 at 7:52 PM
$CMND $IMNN $SBFM $MTVA adm
0 · Reply
hotslots
hotslots Jul. 14 at 6:25 PM
$SBFM whenever cost to borrow is this high you already know stock has no chance
1 · Reply
contra7
contra7 Jul. 14 at 5:03 PM
$SBFM The final hurdle in this international blockbuster acquisition is the Health Canada approval for Sandoz GLP1 generic products for weight loss and diabetes. Sandoz will be the first non domestic company in Canada to gain approval which will trigger the GLP1 turf war with Sandoz’ uber aggressive plan to undercut already discounted prices by 40-50%. This is a highly market sensitive matter that is being handled with extreme care and confidentiality. International acquisitions of this magnitude are highly scrutinized which is why this announcement will be green lit for a very specific window which will likely include a T1 Halt. The MM has been keeping price action contained and is well aware of an impending corporate event and is obviously privy to the extreme over leveraged short positions that will be forced into settlement upon announcement. Due to the highly sensitive nature of this approval Sandoz will announce before HC makes the approval public.
2 · Reply
Jimesica
Jimesica Jul. 14 at 1:26 PM
$SBFM Buyout coming Next Week! Just cut and paste this message every week 🤣
0 · Reply
contra7
contra7 Jul. 14 at 4:01 AM
$SBFM This will be a market event of EPIC PROPORTIONS
1 · Reply